2. Academic Validation
  3. Protective monotherapy against lethal Ebola virus infection by a potently neutralizing antibody

Protective monotherapy against lethal Ebola virus infection by a potently neutralizing antibody

  • Science. 2016 Mar 18;351(6279):1339-42. doi: 10.1126/science.aad5224.
Davide Corti 1,  John Misasi 2,  Sabue Mulangu 2,  Daphne A Stanley 2,  Masaru Kanekiyo 2,  Suzanne Wollen 3,  Aurélie Ploquin 2,  Nicole A Doria-Rose 2,  Ryan P Staupe 2,  Michael Bailey 2,  Wei Shi 2,  Misook Choe 2,  Hadar Marcus 2,  Emily A Thompson 2,  Alberto Cagigi 2,  Chiara Silacci 4,  Blanca Fernandez-Rodriguez 4,  Laurent Perez 4,  Federica Sallusto 4,  Fabrizia Vanzetta 5,  Gloria Agatic 5,  Elisabetta Cameroni 5,  Neville Kisalu 6,  Ingelise Gordon 2,  Julie E Ledgerwood 2,  John R Mascola 2,  Barney S Graham 2,  Jean-Jacques Muyembe-Tamfun 6,  John C Trefry 3,  Antonio Lanzavecchia 7,  Nancy J Sullivan 8
Affiliations

Affiliations

  • 1 Institute for Research in Biomedicine, Università della Svizzera Italiana, CH-6500 Bellinzona, Switzerland. Humabs BioMed SA, 6500 Bellinzona, Switzerland.
  • 2 Vaccine Research Center, National Institute of Allergy and Infectious Diseases, Bethesda, MD 20892, USA.
  • 3 U.S. Army Medical Research Institute of Infectious Diseases, Fort Detrick, MD 21702, USA.
  • 4 Institute for Research in Biomedicine, Università della Svizzera Italiana, CH-6500 Bellinzona, Switzerland.
  • 5 Humabs BioMed SA, 6500 Bellinzona, Switzerland.
  • 6 National Institute for Biomedical Research, National Laboratory of Public Health, Kinshasa B.P. 1197, Democratic Republic of the Congo.
  • 7 Institute for Research in Biomedicine, Università della Svizzera Italiana, CH-6500 Bellinzona, Switzerland. Institute of Microbiology, ETH Zürich, CH-8093 Zürich, Switzerland.
  • 8 Vaccine Research Center, National Institute of Allergy and Infectious Diseases, Bethesda, MD 20892, USA. njsull@mail.nih.gov.
PMID: 26917593 DOI: 10.1126/science.aad5224
Abstract

Ebola virus disease in humans is highly lethal, with case fatality rates ranging from 25 to 90%. There is no licensed treatment or vaccine against the virus, underscoring the need for efficacious countermeasures. We ascertained that a human survivor of the 1995 Kikwit Ebola virus disease outbreak maintained circulating Antibodies against the Ebola virus surface glycoprotein for more than a decade after Infection. From this survivor we isolated monoclonal Antibodies (mAbs) that neutralize recent and previous outbreak variants of Ebola virus and mediate antibody-dependent cell-mediated cytotoxicity in vitro. Strikingly, monotherapy with mAb114 protected macaques when given as late as 5 days after challenge. Treatment with a single human mAb suggests that a simplified therapeutic strategy for human Ebola Infection may be possible.

Figures
Products
  • Cat. No.
    Product Name
    Description
    Target
    Research Area
  • HY-P99337
    99.90%, 抗埃博拉病毒单克隆抗体
嗨！很高兴为您提供帮助！

尊敬的 MCE 客户您好，
请您选择所在区域，我们将转接对应客服为您服务！

热门区域

A

B

C

F

G

H

J

L

N

Q

S

T

X

Y

Z

热 A B C F G H J L N Q S T X Y Z